Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Shanghai Fosun And Chindex CEO Team Up To Capitalize On China’s Growing Private Markets

This article was originally published in PharmAsia News

Executive Summary

As China opens up its private hospital market and a new wave of investment, major players such as Chindex International Inc. are reevaluating and repositioning themselves to benefit from the growing private infrastructure.

Advertisement

Related Content

China's Largest Private Pharma Company Fosun Pharma Targets Biosimilar Market, With Sights On Becoming The Next Teva
Pricing Pressures Lower Profits For Chinese Drug Chain Nepstar, While Healthcare Reform Has Opposite Effect On Hospital Chain Chindex - China Earnings Roundup (Part 1)
Riding High And Scaling Up, Chindex Readies Business Model Rollout In China

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC086304

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel